glp-1 addiction treatment
21% Lower Drinking With GLP-1, Skipping Standard Obesity Treatment
In a 12-week trial, participants receiving semaglutide experienced a 21% drop in heavy-drinking days compared with placebo, while also losing an average of 4 BMI points. This finding suggests GLP-1 drugs can address two chronic conditions at once, reshaping how we think about obesity care. Medical Disclaimer: This article is